×
About 238 results

ALLMedicine™ Afibrinogenemia Center

Research & Reviews  86 results

Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency
https://clinicaltrials.gov/ct2/show/NCT02065882

Jul 27th, 2022 - The present study is designed as a prospective, open-label, multicentre, phase I/III study investigating the 14 day single-dose pharmacokinetic properties, efficacy and safety of BT524 following intravenous administration in the treatment or proph...

Thrombin Time
https://emedicine.medscape.com/article/2086278-print

May 5th, 2022 - Thrombin time is a screening coagulation test designed to assess fibrin formation from fibrinogen in plasma. The reference range for the thrombin time is usually less than 20 seconds (ie, 15-19 seconds), but this depends on the test kit/instrument...

Thrombin Time
http://emedicine.medscape.com/article/2086278-overview

May 5th, 2022 - Reference Range Thrombin time is a screening coagulation test designed to assess fibrin formation from fibrinogen in plasma. The reference range for the thrombin time is usually less than 20 seconds (ie, 15-19 seconds), but this depends on the tes...

Clinical, biological, and genetic features in an afibrinogenemia patient series in Alge...
https://doi.org/10.1111/hae.14579
Haemophilia : the Official Journal of the World Federatio... Hadjali-Saichi S, de Mazancourt P et. al.

May 1st, 2022 - The incidence of afibrinogenemia had not been previously reported in Algeria. Afibrinogenemia patients are prone to both haemorrhagic and thrombotic complications. Predictive markers of thrombosis in afibrinogenemia patients are not existent. Clin...

Medical Management of a Mural Thrombus Inducing Repeated Ischemic Strokes in a Patient ...
https://doi.org/10.1016/j.jstrokecerebrovasdis.2022.106526
Journal of Stroke and Cerebrovascular Diseases : the Offi... Nishihori M, Araki Y et. al.

May 1st, 2022 - Congenital afibrinogenemia is an autosomal recessive inherited disorder that can cause thrombotic as well as hemorrhagic events. We describe a case of repeated mild ischemic strokes due to a mural thrombus in the carotid artery and our medical tre...

see more →

Drugs  2 results

Riastap - fibrinogen human injection, powder, lyophilized, for solution-CSL Behring GmbH
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903dc8d0-39da-462c-9dac-004e0c7a26cc

Jun 15th, 2021 - RIASTAP®, Fibrinogen Concentrate (Human) is a human blood coagulation factor indicated for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogen...

Fibryga - fibrinogen (human) kit-Octapharma USA Inc
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=007a93f4-d84b-1fa9-51ed-32f6140bf423

Dec 22nd, 2020 - FIBRYGA is a human fibrinogen concentrate indicated for the treatment of acute bleeding episodes in adults and children with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. FIBRYGA is not indicated for dysfibrin...

see more →

Clinicaltrials.gov  7 results

Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency
https://clinicaltrials.gov/ct2/show/NCT02065882

Jul 27th, 2022 - The present study is designed as a prospective, open-label, multicentre, phase I/III study investigating the 14 day single-dose pharmacokinetic properties, efficacy and safety of BT524 following intravenous administration in the treatment or proph...

Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Participants With Congenital Afibrinogenemia
https://clinicaltrials.gov/ct2/show/NCT02281500

Mar 31st, 2022 - This study is a phase I-II, multi-center, prospective, open-label, single-arm, clinical trial to evaluate Pharmacokinetic (PK), efficacy, and safety of human plasma-derived fibrinogen concentrate (FIB Grifols) in adult and pediatric participants w...

Safety and Efficacy of Fibryga in Congenital Fibrinogen Deficiency
https://clinicaltrials.gov/ct2/show/NCT03793426

Feb 17th, 2022 - There is a need to increase the body of data on treatment effectiveness and safety in the ultra-rare setting of congenital fibrinogen deficiency. Real-world evidence (RWE) derived from non-interventional studies can describe product utilization, d...

FIB Grifols Congenital Deficiency for On-demand Treatment and Surgical Prophylaxis
https://clinicaltrials.gov/ct2/show/NCT04636268

May 13th, 2021 - This is a phase 3, multi-center, prospective, open-label, single-arm, clinical trial to be carried out in subjects with congenital fibrinogen deficiency manifested as afibrinogenemia or severe hypofibrinogenemia. This clinical trial is planned to ...

Quality of Life in Patients With Congenital Afibrinogenemia
https://clinicaltrials.gov/ct2/show/NCT03484065

Nov 12th, 2020 - In this observational study, children and adults suffering from congenital afibrinogenemia confirmed by biology will be enrolled. All patients will receive a questionnaire on quality of life in their own language during a routine visit and filled ...

see more →